BC Extra | Dec 5, 2019
Company News

Deerfield propels Civetta with $53M series A

Deerfield-backed Civetta Therapeutics LLC is building a platform to systematically identify small molecules targeting β-propeller proteins, a molecular class that has seen little drug development activity despite its ubiquity in the human genome. “There has...
BC Innovations | Mar 10, 2017
Targets & Mechanisms

Poly drugs for polycomb

In parallel studies, Novartis AG and Abbvie Inc. have reported inhibitors of the epigenetic regulator PRC2 that block the protein by a new mechanism, offering a complement to the inhibitors in the clinic, and more...
Items per page:
1 - 2 of 2